An FDA convened panel of medical experts urged the removal of black box warnings on menopausal hormone therapy (MHT), citing benefits outweighing risks in symptomatic relief and potential prevention of cardiovascular and cognitive diseases. The panel criticized reliance on the Women's Health Initiative data informing current labels, describing the findings as outdated and limited. The meeting, led by FDA Commissioner Martin Makary, highlighted growing clinician support for MHT to address severe menopausal symptoms, noting access barriers tied to existing warnings. Some panel members have affiliations with advocacy groups supported by major pharma companies involved in hormone therapies.